AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00830765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2cc of placebo liquid formulated by pharmacy personnel at the University of Mississippi Medical Center injected IM weekly until 34 weeks' gestation has been reached or delivery, whichever occurs first.
Study NCT03508778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FluidVision AIOL
Description: Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
Study NCT03508778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AcrySof IQ PanOptix Trifocal IOL
Description: Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
Study NCT03508778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract surgery per investigator's standard practice
Study NCT03508778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract surgery per investigator's standard practice
Study NCT03854942 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo oral tablet daily
Study NCT03854942 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone
Description: Naltrexone (Nemexin) oral tablet 50 mg daily for 2 days, Naltrexone (Nemexin) oral tablet 100 mg daily for 5 days
Study NCT01241422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 40929837
Description: On Day 1: participants will receive 2 tablets of 50 mg JNJ 40929837 in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 tablet of 50 mg JNJ 40929837 in the morning and 1 JNJ 40929837 50 mg tablet + 1 placebo capsule in the evening; and on Day 7: 1 tablet of 50 mg JNJ 40929837 in the morning.
Study NCT01241422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On Day 1: participants will receive 2 placebo tablets in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 placebo tablet + 1 placebo capsule in the evening; and on Day 7: 1 placebo tablet in the morning.
Study NCT01241422 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast
Description: On Day 1: participants will receive 2 placebo tablets in the morning and 1 montelukast capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 montelukast capsule + 1 placebo tablet in the evening; and on Day 7: 1 placebo tablet in the morning.
Study NCT00969228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix ™
Description: Two oral doses
Study NCT00969228 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two oral doses
Study NCT02563899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium
Description: Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be available at a concentration of 18.5 milligrams (mg) umeclidinium parent per gram. 2 mg of this formulation will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of formulation applied daily to both axillae is expected to range between approximately 204 and 680 mg. Total daily dosage of the active pharmaceutical ingredient (umeclidinium parent) to both axillae will range between approximately 3.8 and 12.6 mg. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects. This lower strength formulation will contain 11.5 mg parent per gram.
Study NCT02563899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. 2 mg of the vehicle will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of vehicle applied daily to both axillae is expected to range between approximately 204 and 680 mg.
Study NCT02755506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endobronchial ultrasound elastography
Description: Before endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), patients will undergo the examination of endobronchial ultrasound elastography
Study NCT05261165 — intervention group
Intervention type: PROCEDURE
Intervention: hysterectomy
Description: Hysterectomy as primary surgical treatment of endometrial cancer. Abdominal laparotomy approach was performed without intrauterine manipulator (NonManip). Endoscopic - total laparoscopic hysterectomy, laparoscopic assisted vaginal hysterectomy or robotic hysterectomy was performed with use of intrauterine manipulator (Manip). It was Hegar dilatator (ManipHe) or Koh-Rumi device (ManipKoRu).
Study NCT04045756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procedure/Surgery: Transperineal Focal Laser Ablation (TPLA)
Description: The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bollous of i.v. corticosteriods () is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Cirpofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
Study NCT04188600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Libicare
Description: The main ingredients of Libicare® are:~* Trigonella Foenum-graecum (Trigonella)~* Tribulus Terrestris (Tribulus)~* Turnera Diffusa (Damiana)
Study NCT04188600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Libicare
Description: The main ingredients of Libicare® are:~* Trigonella Foenum-graecum (Trigonella)~* Tribulus Terrestris (Tribulus)~* Turnera Diffusa (Damiana)
Study NCT04188600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: active control
Description: Selenium and vitamins B complex
Study NCT02031523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sanjie analgesic capsule
Description: Oral, four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.or follow the doctor's advice.
Study NCT02031523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral，four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle. Or Follow the doctor's advice.
Study NCT04281459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIV Treatment Satisfaction Questionnaire status
Description: Administration of pseudoanonymous HIV-TSQs (translated into Italian) to all included patients.
Study NCT04281459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV Treatment Satisfaction Questionnaire status
Description: Administration of pseudoanonymous HIV-TSQs (translated into Italian) to all included patients.
Study NCT02053792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rIX-FP
Description: Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
Study NCT04108143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MonitorMe
Description: MonitorMe replaces the users existing telephone and for the majority of time is used as their ordinary telephone. At a known and set time of day for 4 weeks, participants will receive an automated MonitorMe telephone call. The participant answers a health and well-being automated script by pressing key pad numbers. At the same time vital signs data are collected. The responses and vital signs data, together with confidence values are then transmitted via telephone lines to an electronic patient record.
Study NCT04743089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERCP using SpyGlass™ DS Direct Visualization System
Description: Lithotripsy and stone removal will be performed using ERCP and Spyglass system to patients with IHD/EHD stone, which is difficult to remove through conventional ERCP. The SpyGlass™ DS Direct Visualization System will be applied directly into the bile duct via the working channel of the duodenoscope. Under the high-resolution digital imaging, lithotripsy such as EHL could be done.
Study NCT03149549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-2009
Description: CX-2009 Monotherapy
Study NCT00728910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 10 mg QD for 4 weeks
Study NCT04743089 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PTCS
Description: A historical cohort of patients who underwent PTCS to remove bile duct stones which is difficult to treat by ERCP.
Study NCT01146847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space TGC
Description: Space TGC with incorporated eMPC algorithm to establish tight glycaemic control with a blood glucose target range of 80-110 mg/dL (4.4-6.1 mM)
Study NCT02404545 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ethicon Physiomesh
Description: Ethicon Physiomesh will be paced at the time of radical cystectomy and ileal conduit.
Study NCT02821494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hespecta
Description: A dose escalation of Amplivant® conjugated peptide
Study NCT04778852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: EksoGT
Description: EksoGT is an overground wearable gait trainer. The therapy will be carried out 3 days a week for 4 weeks.
Study NCT04778852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional kinematic training
Description: Device: No device. The functional kinematic training will be delivered as comparator treatment and will be carried out 3 days a week for 4 weeks.
Study NCT05355558 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]FLT-PET/MRI body scan
Description: \[18F\]FLT-PET/MRI body scan will be done at~* Visit 2 (Baseline-Pre-Treatment FLT-PET/MRI) which will occur between 1 to 28 days prior to initiation of radiotherapy.~* Visit 3 (During Treatment FLT-PET/MRI) which will occur between week 4 to week 5 of External Beam Radiotherapy (before brachytherapy).~At these visits:~* Obtain vital signs and weight in kg before FLT administration.~* Record the dose of FLT received and injected. (\*\*specify dose: 1mCi per 10kg. Maximum injected dose: \< 10mCi per patient.)~* Place one (1) IV catheters into the participant's arm vein to inject the bolus of FLT.~* Perform a saline flush following the FLT injection.~* Body PET/MRI will be performed after FLT injection.~* Time of injection of FLT and time of scan will need to be recorded.
Study NCT01890655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-Low
Study NCT00728910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT335
Description: 135 mg QD added to atorvastatin for 8 weeks
Study NCT00728910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ER Niacin
Description: 2000 mg QD added to atorvastatin and ABT335 for 10 weeks
Study NCT01890655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-Middle
Study NCT01890655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-High
Study NCT03934671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antioxidant dressing (active product)
Description: Antioxidant dressing (active product), covered with secondary dressing. Compression bandage if necessary.~Device: Reoxcare®
Study NCT03934671 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care dressing that create a moist environment (standard clinical practice)
Description: Usual care dressing; moist environment dressing chosen from the study centres' formulary (hydrocolloid, alginate, polyurethane foam dressings, silver dressings). Compression bandage if necessary
Study NCT01814007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq CoolSculpting System
Description: Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study NCT00037986 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hearing Aids
Description: Hearing aid use
Study NCT04378335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: completion of questionnaire
Description: parents have to complete 2 questionnaires: demographic questionnaire and Montréal questionnaire when they come on allergy consultation.
Study NCT04022317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biocon Insulin R
Description: Biocon Insulin R is a short-acting human insulin, produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing Pichia pastoris (yeast).
Study NCT04022317 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humulin®R
Description: Humulin® R is a polypeptide hormone structurally identical to human insulin synthesised through recombinant deoxyribonucleic acid (rDNA) technology in a non-pathogenic laboratory strain of Escherichia coli bacteria.
Study NCT03546673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulation Condition
Study NCT03546673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Disclosure Condition
Study NCT04350827 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Platelet rich plasma injection into patellar tendon
Study NCT04350827 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma plus IGF
Description: Platelet rich plasma plus IGF injection into patellar tendon
Study NCT03187743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples at 3 visits :~V0 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis~V1 : - 5 mL in heparin tube / sample (2 to 5 samples) Pharmacokinetics + Pharmacogenetics + Gene Expression Analysis~V2 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis and - 5 mL in EDTA tube / DNA bank
Study NCT03539276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knowledge exchange
Description: OptimaMed
Study NCT03515863 — intervention group
Intervention type: GENETIC
Intervention: DNA extraction and genetic characterization
Description: Collection of blood samples for DNA extraction and genetic characterization using whole-genome sequencing, and for identification of cellular biomarkers using transcriptomics and mass cytometry.
Study NCT03515863 — intervention group
Intervention type: DEVICE
Intervention: Orbit MRI examination
Description: Orbit MRI examination is performed to confirm the diagnosis of TAO
Study NCT03515863 — intervention group
Intervention type: OTHER
Intervention: Collection of life style data
Description: Collection of life style data using quality of life questionnaire
Study NCT00898430 — intervention group
Intervention type: GENETIC
Intervention: DNA Microarray analysis
Description: Tumors will be assayed on Affymetrix Human Genome U133 GeneChip
Study NCT00898430 — intervention group
Intervention type: GENETIC
Intervention: MALDI-TOF mass spectrometry
Description: Supervised analysis techniques will be employed to identify patterns of protein peaks useful for treatment response and survival prediction. Hierarchical clustering analyses will be used to visualize data.
Study NCT00898430 — intervention group
Intervention type: GENETIC
Intervention: DNA microarray and MALDI-TOF mass spectrometry
Description: Tumors from the specific Aim 1/2 and from preliminary data, previously analyzed, will be examined for HPV 16 infection.
Study NCT03663270 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypotension probability index (HPI)
Description: The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
Study NCT02112695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]diprenorphine
Description: 3 micrograms \[11C\]diprenorphine - intravenous use - 1 time
Study NCT02728232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: internal iliac artery ligation
Study NCT02728232 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean Hysterectomy
Study NCT02728232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cesarean Hysterectomy
Study NCT04588974 — intervention group
Intervention type: DEVICE
Intervention: magnetic-assisted capsule endoscope system (InsightEyes EGD System) with or without 3D images
Description: The patient will undergo both diagnostic tests within two days, a magnetic-assisted capsule endoscope system first and then conventional EGD will be carried on at least 4 hours afterward.
Study NCT01087164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compliance
Description: Parent will either receive a high or no compliance condition where each is asked to endorse the importance of prevention cervical cancer or genital warts depending on their teen's gender.
Study NCT01087164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message sidedness
Description: Parent will receive either a one-sided or two-sided message about the HPV vaccine
Study NCT03106116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Enhanced External Counterpulsation
Description: Enhanced External Counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy has been approved by the United States Food and Drug Administration (FDA) for the treatment of refractory angina and heart failure. Administration of 35-36 hours EECP therapy over a 7 week period, one hour session every working day.
Study NCT03106116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy
Description: Guideline- driven standard medical treatment for 7 weeks
Study NCT03106116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medical therapy
Description: Guideline- driven standard medical treatment for 7 weeks
Study NCT03638128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Solution for injection
Study NCT03638128 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alternative osteoporosis medications
Description: Alternative osteoporosis medication/s at the discretion of the investigator.
Study NCT02737761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qualitative Interview and Adherence Measurements
Description: Subjects will undergo an open-ended, semi-structured interview within two weeks of enrollment. The interview will be approximately 1 hour in length, performed by study staff who have been trained in qualitative research methods. This interview will be completed again 12 weeks later. Subjects will complete the MOS SAS, Automated Self-Administered 24-hour recall (ASA24), Life Orientation Test-Revised (LOT-R), Positive and Negative Affect Schedule (PANAS), Hospital Anxiety and Depression Scale (HADS), Kansas City Cardiomyopathy Questionnaire (KCCQ), and Medical Outcomes Study Short Form-12 (SF-12) at baseline and again at 12 weeks.
Study NCT01856738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Capsule. Dose 3,0 - 6,0 mg BID
Study NCT01856738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for rivastigmine)
Description: Capsule. Dose 3,0 - 6,0 mg BID
Study NCT01228591 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Acuvue Advance Plus
Description: Silicone hydrogel contact lens.
Study NCT01228591 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Acuvue Advance
Description: Silicone hydrogel contact lens
Study NCT01023607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 20mg/day
Study NCT01023607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin, 60mg/day
Study NCT01023607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin,10mg/day
Study NCT02626598 — intervention group
Intervention type: DEVICE
Intervention: Blended Belotero
Description: Belotero blended with 0.1 cc of 1% lidocaine with epinephrine per 1.0 cc Belotero will be injected to etched in fine facial lines
Study NCT04656613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: the Gam-COVID-Vac is combined 2 -component vector vaccine against the SARS-СoV-2-induced coronavirus infection
Study NCT04656613 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo Comparator
Study NCT01288599 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery
Description: Laparoscopic surgery where adnexectomy or cystectomy is performed.
Study NCT01288599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: Laparoscopic surgery where adnexectomy or cystectomy is performed.